Harnessing innate immunity in cancer therapy.
发布时间:2019/10/25 09:12:40

New therapies that promote antitumour immunity have been recently developed. Most of these immunomodulatory approaches have focused on enhancing T-cell responses, either by targeting inhibitory pathways with immune checkpoint inhibitors, or by targeting activating pathways, as with chimeric antigen receptor T cells or bispecific antibodies. Although these therapies have led to unprecedented successes, only a minority of patients with cancer benefit from these treatments, highlighting the need to identify new cells and molecules that could be exploited in the next generation of immunotherapy. Given the crucial role of innate immune responses in immunity, harnessing these responses opens up new possibilities for long-lasting, multilayered tumour control.

 2019 Oct;574(7776):45-56. doi: 10.1038/s41586-019-1593-5. Epub 2019 Oct 2.


版权所有:济宁医学院精准医学研究院  地址:济宁市北湖新区荷花路133号科研楼三楼  邮编:272067